| Stereochemistry | RACEMIC |
| Molecular Formula | C18H18N2 |
| Molecular Weight | 262.3489 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1C(C2=NCCN2)C1(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=IPOBOOXFSRWSHL-UHFFFAOYSA-N
InChI=1S/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20)
| Molecular Formula | C18H18N2 |
| Molecular Weight | 262.3489 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Cibenzoline is a class I sodium channel blocker
antiarrhythmic drug available in a limited number
of countries. Cibenzoline also has moderate calcium channel blocking (class IV) effects and prolongs the action potential duration through its potassium channel blocking (class III) effect. It is used for the treatment of supraventricular and ventricular arrhythmias, and in obstructive hypertrophic cardiomyopathy.
